P490 Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials

Vermeire, Séverine; Peyrin‐Biroulet, Laurent; Panés, Julián; Regueiro, Miguel; Gustavo Kotze, Paulo; Charabaty, A; Goetsch, M; Shan, Kevin; Wu, Joseph; McDonnell, A; Woolcott, John; Danese, Silvio

doi:10.1093/ecco-jcc/jjac190.0620

Public

P490 Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials

Shared by NobleBlocks on Jan 30, 2023 • 12:00 AM UTC

Authors:

Séverine Vermeire

Laurent Peyrin‐Biroulet

Julián Panés

Abstract

Abstract Background Etrasimod is an investigational, once-daily, oral, selective sphingosine 1-phosphate receptor 1,4,5 (S1P1,4,5) modulator in development for the treatment of moderately to severely active ulcerative colitis (UC). The safety and efficacy of etrasimod for the treatment of moderate t...

Subject

Medicine

Ulcerative colitis

Adverse effect

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!